KLRA vs NVO
KLRA: Kailera Therapeutics is a clinical-stage biotechnology company advancing a diversified pipeline of GLP-1-based therapies for the treatment of obesity. NVO: A global healthcare leader specializing in innovative treatments for diabetes, obesity, and other serious chronic conditions.
Side-by-side fundamentals
| Metric | KLRA | NVO | Edge |
|---|---|---|---|
| Price as of 2026-10-22 close | $13.27 | $39.43 | |
| Market cap | $1.7B | $175.2B | |
| Net margin FY2025, SEC XBRL | n/a | +33.1% | |
| Gross margin FY2025, SEC XBRL | n/a | +81.0% | |
| Operating margin FY2025, SEC XBRL | n/a | +41.3% | |
| ROE FY2025, SEC XBRL | n/a | +52.8% | |
| ROA FY2025, SEC XBRL | n/a | +18.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +20.4% | |
| Dividend yield as of 2026-09-03 | n/a | +2.7% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 2.14 | 0.81 | |
| 1-year return as of 2026-10-22 close | n/a | -26.1% |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.